Holen Sie sich die Stockscreener-App
16.77
2.95%
-0.5088
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Transcript : Apellis Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Mizuho Securities Adjusts Apellis Pharmaceuticals Price Target to $20 From $30, Maintains Neutral Rating - marketscreener.com
APLS: Apellis Pharmaceuticals Stock Downgraded by B of A Securit - GuruFocus
Raymond James Downgrades Apellis Pharmaceuticals (BIT:1APLS) - Nasdaq
Raymond James Downgrades Apellis Pharmaceuticals (APLS) with Pri - GuruFocus
Sector Update: Health Care - marketscreener.com
Apellis Pharmaceuticals Stumbles Over Funding And Sales Hurdles - Finimize
Raymond James Downgrades Apellis Pharmaceuticals (APLS) with Price Target Cut | APLS Stock News - GuruFocus
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down - MSN
Apellis Pharmaceuticals downgraded by Raymond James due to ’added uncertainty’ - Investing.com Canada
Is Apellis Pharmaceuticals, Inc. (APLS) The Best Stock That Will Bounce Back? - Insider Monkey
BofA Adjusts Apellis (APLS) Rating to Neutral, Lowers Price Targ - GuruFocus
Apellis (APLS) Faces Downgrade Amid Sales Volatility Concerns | - GuruFocus
Analysts Just Slashed Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) EPS Numbers - simplywall.st
BofA Adjusts Apellis (APLS) Rating to Neutral, Lowers Price Target | APLS Stock News - GuruFocus
Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say - MSN
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates - MSN
11 Stocks That Will Bounce Back According to Analysts - Insider Monkey
Apellis Pharmaceuticals (APLS) Analyst Rating Update by RBC Capi - GuruFocus
Apellis Pharmaceuticals (APLS) Analyst Rating Update by RBC Capital | APLS Stock News - GuruFocus
Apellis (APLS) Price Target Reduced by Scotiabank Analyst | APLS Stock News - GuruFocus
Apellis Pharmaceuticals (APLS) Price Target Lowered by Scotiabank | APLS Stock News - GuruFocus
Apellis Pharmaceuticals (APLS): Wells Fargo Lowers Price Target to $26 | APLS Stock News - GuruFocus
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2025 Earnings Call Transcript - Insider Monkey
Apellis Pharmaceuticals (APLS) Target Price Lowered by Analyst | APLS Stock News - GuruFocus
Optimistic Growth Potential for Apellis Pharmaceuticals Despite Temporary Setbacks - TipRanks
Apellis Pharmaceuticals (APLS) Price Target Reduced by Analyst | APLS Stock News - GuruFocus
Apellis Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Apellis Pharmaceuticals Inc (APLS) Q1 2025 Earnings Call Highlights: Strong Market Leadership ... - Yahoo Finance
Fierce Biotech Layoff Tracker 2025: Insitro shrinks team by 22%; Shape ships out staff - Fierce Biotech
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results - Barchart.com
Decoding Apellis Pharmaceuticals Inc (APLS): A Strategic SWOT In - GuruFocus
Apellis Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Why Apellis Pharmaceuticals (APLS) Stock is Declining - GuruFocus
Why Apellis Pharmaceuticals Wilted on Wednesday - MSN
APLS: Apellis Pharmaceuticals Maintains Buy Rating Amid Price Target Cut | APLS Stock News - GuruFocus
Transcript : Apellis Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com
Earnings call transcript: Apellis Pharmaceuticals misses Q1 2025 estimates By Investing.com - Investing.com Nigeria
Earnings call transcript: Apellis Pharmaceuticals misses Q1 2025 estimates - Investing.com
Apellis Pharmaceuticals stock tumbles on Q1 revenue miss, inventory issues By Investing.com - Investing.com Nigeria
Apellis Pharmaceuticals stock tumbles on Q1 revenue miss, inventory issues - Investing.com
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results - The Manila Times
Apellis (APLS) Sees Q1 Revenue Miss as Strategic Growth Continues | APLS Stock News - GuruFocus
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
BRIEF-Apellis Pharmaceuticals Q1 Basic EPS USD -0.74 - TradingView
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - TradingView
Apellis Pharmaceuticals Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - Louisiana First News
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
Press Release Distribution & PR Platform - ACCESS Newswire
Apellis Pharmaceuticals to Present Q1 2025 Results: Complement Medicine Leader's Financial Update - Stock Titan
Apellis (APLS) Receives Overweight Rating and Positive Outlook f - GuruFocus
(APLS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Cantor Fitzgerald Initiates Coverage of Apellis Pharmaceuticals (APLS) with Overweight Recommendation - msn.com
Is Apellis Pharmaceuticals, Inc. (APLS) the Best Oversold NASDAQ Stock to Buy Right Now? - Insider Monkey
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):